IL-6, as a key upstream regulator of JAK/STAT signaling, can activate STAT3 and related downstream molecules, enhance thrombopoietin expression, and drive excessive myeloid proliferation, ultimately leading to secondary (reactive) thrombocytosis (14). This evidence concerns the gene THPO and thrombocytosis disease.